• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制人类免疫反应的B7-1/CTLA-4复合物的晶体结构。

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.

作者信息

Stamper C C, Zhang Y, Tobin J F, Erbe D V, Ikemizu S, Davis S J, Stahl M L, Seehra J, Somers W S, Mosyak L

机构信息

Departments of Biological Chemistry and Musculoskeletal Sciences, Wyeth Research, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140, USA.

出版信息

Nature. 2001 Mar 29;410(6828):608-11. doi: 10.1038/35069118.

DOI:10.1038/35069118
PMID:11279502
Abstract

Optimal immune responses require both an antigen-specific and a co-stimulatory signal. The shared ligands B7-1 and B7-2 on antigen-presenting cells deliver the co-stimulatory signal through CD28 and CTLA-4 on T cells. Signalling through CD28 augments the T-cell response, whereas CTLA-4 signalling attenuates it. Numerous animal studies and recent clinical trials indicate that manipulating these interactions holds considerable promise for immunotherapy. With the consequences of these signals well established, and details of the downstream signalling events emerging, understanding the molecular nature of these extracellular interactions becomes crucial. Here we report the crystal structure of the human CTLA-4/B7-1 co-stimulatory complex at 3.0 A resolution. In contrast to other interacting cell-surface molecules, the relatively small CTLA-4/B7-1 binding interface exhibits an unusually high degree of shape complementarity. CTLA-4 forms homodimers through a newly defined interface of highly conserved residues. In the crystal lattice, CTLA-4 and B7-1 pack in a strikingly periodic arrangement in which bivalent CTLA-4 homodimers bridge bivalent B7-1 homodimers. This zipper-like oligomerization provides the structural basis for forming unusually stable signalling complexes at the T-cell surface, underscoring the importance of potent inhibitory signalling in human immune responses.

摘要

最佳免疫反应需要抗原特异性信号和共刺激信号。抗原呈递细胞上的共享配体B7-1和B7-2通过T细胞上的CD28和CTLA-4传递共刺激信号。通过CD28发出的信号增强T细胞反应,而CTLA-4信号则使其减弱。大量动物研究和近期临床试验表明,操纵这些相互作用在免疫治疗方面具有巨大潜力。随着这些信号的后果已得到充分证实,并且下游信号事件的细节不断涌现,了解这些细胞外相互作用的分子本质变得至关重要。在此,我们报告了人CTLA-4/B7-1共刺激复合物的晶体结构,分辨率为3.0埃。与其他相互作用的细胞表面分子不同,相对较小的CTLA-4/B7-1结合界面表现出异常高的形状互补性。CTLA-4通过高度保守残基的新定义界面形成同二聚体。在晶格中,CTLA-4和B7-1以惊人的周期性排列堆积,其中二价CTLA-4同二聚体桥接二价B7-1同二聚体。这种拉链样寡聚化提供了在T细胞表面形成异常稳定信号复合物的结构基础,强调了有效抑制信号在人类免疫反应中的重要性。

相似文献

1
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.抑制人类免疫反应的B7-1/CTLA-4复合物的晶体结构。
Nature. 2001 Mar 29;410(6828):608-11. doi: 10.1038/35069118.
2
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.人CTLA-4/B7-2复合物共刺激的结构基础。
Nature. 2001 Mar 29;410(6828):604-8. doi: 10.1038/35069112.
3
T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.对葡萄球菌肠毒素B耐受的自身免疫性MRL-lpr/lpr小鼠的T细胞需要通过B7-CD28/CTLA-4途径进行共刺激才能激活,并且在缺乏这种共刺激信号的情况下,通过刺激T细胞受体可在体内再次失能。
Eur J Immunol. 1994 May;24(5):1019-25. doi: 10.1002/eji.1830240502.
4
A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.一种能选择性结合细胞毒性T淋巴细胞相关抗原4(CTLA-4)的突变型B7-1/免疫球蛋白(Ig)融合蛋白可改善抗肿瘤DNA疫苗接种效果并对抗调节性T细胞活性。
Vaccine. 2005 Aug 31;23(37):4553-64. doi: 10.1016/j.vaccine.2005.05.002.
5
Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.CD28:B7和CTLA-4:B7通路在调节MHC不相合T细胞小鼠受体体内同种异体反应中的相反作用。
J Immunol. 1999 Jun 1;162(11):6368-77.
6
Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population.针对CTLA-4阻断的T细胞功能的反常抑制;人类T细胞群体内的异质性
Nat Med. 2000 Feb;6(2):211-4. doi: 10.1038/72323.
7
Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).CTLA-4替代对人CD80(B7-1)和CD86(B7-2)结合的差异效应
J Immunol. 1996 Feb 1;156(3):1047-54.
8
Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses.抗原特异性免疫应答过程中gp39与B7表达及功能的相互依赖性研究。
Eur J Immunol. 1995 Feb;25(2):596-603. doi: 10.1002/eji.1830250243.
9
Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.人类外周血树突状细胞的激活可诱导共刺激分子CD86的产生。
Eur J Immunol. 1995 Jul;25(7):2064-8. doi: 10.1002/eji.1830250739.
10
Refolding and characterization of recombinant human soluble CTLA-4 expressed in Escherichia coli.在大肠杆菌中表达的重组人可溶性细胞毒性T淋巴细胞相关抗原4的复性与鉴定
Protein Expr Purif. 1999 Oct;17(1):26-32. doi: 10.1006/prep.1999.1093.

引用本文的文献

1
Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies.霍奇金淋巴瘤及其他血液系统恶性肿瘤中的免疫检查点分子
Cancers (Basel). 2025 Jul 10;17(14):2292. doi: 10.3390/cancers17142292.
2
Negative Immune Checkpoint Inhibitors.阴性免疫检查点抑制剂
Pharmaceutics. 2025 May 28;17(6):713. doi: 10.3390/pharmaceutics17060713.
3
Spatial and stoichiometric in situ analysis of biomolecular oligomerization at single-protein resolution.单蛋白分辨率下生物分子寡聚化的空间和化学计量原位分析。
Nat Commun. 2025 May 6;16(1):4202. doi: 10.1038/s41467-025-59500-z.
4
The Structural Biology of T-Cell Antigen Detection at Close Contacts.紧密接触时T细胞抗原检测的结构生物学
Immunol Rev. 2025 May;331(1):e70014. doi: 10.1111/imr.70014.
5
Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.免疫检查点的翻译后修饰:开启癌症免疫治疗的新潜力。
Exp Hematol Oncol. 2025 Mar 14;14(1):37. doi: 10.1186/s40164-025-00627-6.
6
The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies.不同微卫星不稳定性(MSI)状态的结直肠癌肿瘤免疫微环境特征及当前治疗策略
Front Immunol. 2025 Jan 14;15:1440830. doi: 10.3389/fimmu.2024.1440830. eCollection 2024.
7
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma.基于抗体的肝细胞癌免疫治疗的结构见解
Genomics Inform. 2025 Jan 20;23(1):1. doi: 10.1186/s44342-024-00033-0.
8
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.免疫检查点抑制剂相关的皮肤不良事件:发生机制
Int J Mol Sci. 2024 Dec 26;26(1):88. doi: 10.3390/ijms26010088.
9
Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.纳米抗体作为创新的免疫检查点调节剂:推动癌症免疫治疗
Med Oncol. 2024 Dec 24;42(1):36. doi: 10.1007/s12032-024-02588-y.
10
Research progress of CD80 in the development of immunotherapy drugs.CD80 在免疫治疗药物发展中的研究进展。
Front Immunol. 2024 Nov 7;15:1496992. doi: 10.3389/fimmu.2024.1496992. eCollection 2024.